How Big Will the SpaceX IPO Be?
Operated up to now as a private business, SpaceX will…
Buy
60
DOUG Quote, Financials, Valuation and Earnings
Last price:
$2.71
Seasonality move
:
-25.57%
Day range:
$2.60 - $2.75
52-week range:
$1.48 - $3.20
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
0.22x
P/B ratio:
2.09x
Volume:
556K
Avg. volume:
538K
1-year change:
37.56%
Market cap:
$240.7M
Revenue:
$995.7M
EPS (TTM):
-$0.70
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
DOUG
Douglas Elliman, Inc.
|
$233.7M | -$0.08 | 12.24% | -66.67% | $3.00 |
|
AEI
Alset, Inc.
|
-- | -- | -- | -- | -- |
|
AXR
AMREP Corp.
|
$14M | -- | 86.17% | -- | $23.00 |
|
UCASU
UC Asset LP
|
-- | -- | -- | -- | -- |
|
VGLS
VG Life Sciences
|
-- | -- | -- | -- | -- |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
DOUG
Douglas Elliman, Inc.
|
$2.71 | $3.00 | $240.7M | -- | $0.00 | 0% | 0.22x |
|
AEI
Alset, Inc.
|
$2.82 | -- | $109.7M | -- | $0.00 | 0% | 3.73x |
|
AXR
AMREP Corp.
|
$20.96 | $23.00 | $111.2M | 10.72x | $0.00 | 0% | 2.45x |
|
UCASU
UC Asset LP
|
$0.43 | -- | $2.3M | 329.22x | $0.00 | 0% | 3.47x |
|
VGLS
VG Life Sciences
|
$0.0001 | -- | $2.1M | -- | $0.00 | 0% | -- |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
DOUG
Douglas Elliman, Inc.
|
55.38% | 2.995 | 56.19% | 1.48x |
|
AEI
Alset, Inc.
|
1.55% | 2.485 | 2.27% | 9.30x |
|
AXR
AMREP Corp.
|
0.02% | 1.521 | 0.02% | 11.04x |
|
UCASU
UC Asset LP
|
-- | 10.279 | -- | -- |
|
VGLS
VG Life Sciences
|
-- | 0.000 | -- | -- |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
DOUG
Douglas Elliman, Inc.
|
$44.3M | -$21.6M | -19.99% | -40.12% | -8.23% | $4.7M |
|
AEI
Alset, Inc.
|
$242.5K | -$2M | -12.83% | -13.18% | -201.01% | $822.4K |
|
AXR
AMREP Corp.
|
$3.1M | $1.1M | 8.05% | 8.06% | 11.91% | -$4.3M |
|
UCASU
UC Asset LP
|
-- | -- | -- | -- | -- | -- |
|
VGLS
VG Life Sciences
|
-- | -- | -- | -- | -- | -- |
Douglas Elliman, Inc. vs. Competitors
-
Which has Higher Returns DOUG or AEI?
Alset, Inc. has a net margin of -9.49% compared to Douglas Elliman, Inc.'s net margin of -804.47%. Douglas Elliman, Inc.'s return on equity of -40.12% beat Alset, Inc.'s return on equity of -13.18%.
Company Gross Margin Earnings Per Share Invested Capital DOUGDouglas Elliman, Inc.16.87% -$0.29 $257.6M AEIAlset, Inc.24.28% $0.05 $166.8M -
What do Analysts Say About DOUG or AEI?
Douglas Elliman, Inc. has a consensus price target of $3.00, signalling upside risk potential of 18.08%. On the other hand Alset, Inc. has an analysts' consensus of -- which suggests that it could fall by --. Given that Douglas Elliman, Inc. has higher upside potential than Alset, Inc., analysts believe Douglas Elliman, Inc. is more attractive than Alset, Inc..
Company Buy Ratings Hold Ratings Sell Ratings DOUGDouglas Elliman, Inc.1 1 0 AEIAlset, Inc.0 0 0 -
Is DOUG or AEI More Risky?
Douglas Elliman, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Alset, Inc. has a beta of 1.426, suggesting its more volatile than the S&P 500 by 42.563%.
-
Which is a Better Dividend Stock DOUG or AEI?
Douglas Elliman, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Alset, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Douglas Elliman, Inc. pays -- of its earnings as a dividend. Alset, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios DOUG or AEI?
Douglas Elliman, Inc. quarterly revenues are $262.8M, which are larger than Alset, Inc. quarterly revenues of $998.8K. Douglas Elliman, Inc.'s net income of -$24.9M is lower than Alset, Inc.'s net income of $2M. Notably, Douglas Elliman, Inc.'s price-to-earnings ratio is -- while Alset, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Douglas Elliman, Inc. is 0.22x versus 3.73x for Alset, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income DOUGDouglas Elliman, Inc.0.22x -- $262.8M -$24.9M AEIAlset, Inc.3.73x -- $998.8K $2M
-
Which has Higher Returns DOUG or AXR?
AMREP Corp. has a net margin of -9.49% compared to Douglas Elliman, Inc.'s net margin of 12.77%. Douglas Elliman, Inc.'s return on equity of -40.12% beat AMREP Corp.'s return on equity of 8.06%.
Company Gross Margin Earnings Per Share Invested Capital DOUGDouglas Elliman, Inc.16.87% -$0.29 $257.6M AXRAMREP Corp.32.72% $0.22 $136.1M -
What do Analysts Say About DOUG or AXR?
Douglas Elliman, Inc. has a consensus price target of $3.00, signalling upside risk potential of 18.08%. On the other hand AMREP Corp. has an analysts' consensus of $23.00 which suggests that it could grow by 9.73%. Given that Douglas Elliman, Inc. has higher upside potential than AMREP Corp., analysts believe Douglas Elliman, Inc. is more attractive than AMREP Corp..
Company Buy Ratings Hold Ratings Sell Ratings DOUGDouglas Elliman, Inc.1 1 0 AXRAMREP Corp.1 0 0 -
Is DOUG or AXR More Risky?
Douglas Elliman, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison AMREP Corp. has a beta of 1.443, suggesting its more volatile than the S&P 500 by 44.267%.
-
Which is a Better Dividend Stock DOUG or AXR?
Douglas Elliman, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. AMREP Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Douglas Elliman, Inc. pays -- of its earnings as a dividend. AMREP Corp. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios DOUG or AXR?
Douglas Elliman, Inc. quarterly revenues are $262.8M, which are larger than AMREP Corp. quarterly revenues of $9.4M. Douglas Elliman, Inc.'s net income of -$24.9M is lower than AMREP Corp.'s net income of $1.2M. Notably, Douglas Elliman, Inc.'s price-to-earnings ratio is -- while AMREP Corp.'s PE ratio is 10.72x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Douglas Elliman, Inc. is 0.22x versus 2.45x for AMREP Corp.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income DOUGDouglas Elliman, Inc.0.22x -- $262.8M -$24.9M AXRAMREP Corp.2.45x 10.72x $9.4M $1.2M
-
Which has Higher Returns DOUG or UCASU?
UC Asset LP has a net margin of -9.49% compared to Douglas Elliman, Inc.'s net margin of --. Douglas Elliman, Inc.'s return on equity of -40.12% beat UC Asset LP's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital DOUGDouglas Elliman, Inc.16.87% -$0.29 $257.6M UCASUUC Asset LP-- -- -- -
What do Analysts Say About DOUG or UCASU?
Douglas Elliman, Inc. has a consensus price target of $3.00, signalling upside risk potential of 18.08%. On the other hand UC Asset LP has an analysts' consensus of -- which suggests that it could grow by 834.6%. Given that UC Asset LP has higher upside potential than Douglas Elliman, Inc., analysts believe UC Asset LP is more attractive than Douglas Elliman, Inc..
Company Buy Ratings Hold Ratings Sell Ratings DOUGDouglas Elliman, Inc.1 1 0 UCASUUC Asset LP0 0 0 -
Is DOUG or UCASU More Risky?
Douglas Elliman, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison UC Asset LP has a beta of 3.020, suggesting its more volatile than the S&P 500 by 201.974%.
-
Which is a Better Dividend Stock DOUG or UCASU?
Douglas Elliman, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. UC Asset LP offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Douglas Elliman, Inc. pays -- of its earnings as a dividend. UC Asset LP pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios DOUG or UCASU?
Douglas Elliman, Inc. quarterly revenues are $262.8M, which are larger than UC Asset LP quarterly revenues of --. Douglas Elliman, Inc.'s net income of -$24.9M is higher than UC Asset LP's net income of --. Notably, Douglas Elliman, Inc.'s price-to-earnings ratio is -- while UC Asset LP's PE ratio is 329.22x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Douglas Elliman, Inc. is 0.22x versus 3.47x for UC Asset LP. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income DOUGDouglas Elliman, Inc.0.22x -- $262.8M -$24.9M UCASUUC Asset LP3.47x 329.22x -- --
-
Which has Higher Returns DOUG or VGLS?
VG Life Sciences has a net margin of -9.49% compared to Douglas Elliman, Inc.'s net margin of --. Douglas Elliman, Inc.'s return on equity of -40.12% beat VG Life Sciences's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital DOUGDouglas Elliman, Inc.16.87% -$0.29 $257.6M VGLSVG Life Sciences-- -- -- -
What do Analysts Say About DOUG or VGLS?
Douglas Elliman, Inc. has a consensus price target of $3.00, signalling upside risk potential of 18.08%. On the other hand VG Life Sciences has an analysts' consensus of -- which suggests that it could fall by --. Given that Douglas Elliman, Inc. has higher upside potential than VG Life Sciences, analysts believe Douglas Elliman, Inc. is more attractive than VG Life Sciences.
Company Buy Ratings Hold Ratings Sell Ratings DOUGDouglas Elliman, Inc.1 1 0 VGLSVG Life Sciences0 0 0 -
Is DOUG or VGLS More Risky?
Douglas Elliman, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison VG Life Sciences has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock DOUG or VGLS?
Douglas Elliman, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. VG Life Sciences offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Douglas Elliman, Inc. pays -- of its earnings as a dividend. VG Life Sciences pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios DOUG or VGLS?
Douglas Elliman, Inc. quarterly revenues are $262.8M, which are larger than VG Life Sciences quarterly revenues of --. Douglas Elliman, Inc.'s net income of -$24.9M is higher than VG Life Sciences's net income of --. Notably, Douglas Elliman, Inc.'s price-to-earnings ratio is -- while VG Life Sciences's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Douglas Elliman, Inc. is 0.22x versus -- for VG Life Sciences. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income DOUGDouglas Elliman, Inc.0.22x -- $262.8M -$24.9M VGLSVG Life Sciences-- -- -- --
Related Companies
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Where Will ISRG Stock Be in 5 Years?
Intuitive Surgical (NASDAQ:ISRG) is the innovative medical tech business behind…
Is Kratos Stock a Good Investment?
UAV and hypersonic system defense contractor Kratos (NASDAQ:KTOS) has swung…
Stock Ideas
Buy
56
Is NVDA Stock a Buy?
Market Cap: $4.5T
P/E Ratio: 63x
Buy
61
Is AAPL Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 37x
Buy
53
Is GOOG Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 30x
Alerts
Sell
40
BILL alert for Feb 7
Bill Holdings, Inc. [BILL] is up 37.11% over the past day.
Buy
75
PRLB alert for Feb 7
Proto Labs, Inc. [PRLB] is up 28.33% over the past day.
Sell
30
MSTR alert for Feb 7
Strategy, Inc. [MSTR] is up 26.08% over the past day.
